65,437 trials
Acute Pain · Fever
Primary: Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE). — 77; 86; 26 Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months…
Dupuytren's Disease
Primary: Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint. — 91.3; 0 % Joints
Psoriasis
Primary: Number of Subjects With Treatment Success, Assessed Per the Investigator's Static Global Assessment — 58; 17 participants — p=0.016
Psoriasis
Primary: Number of Subjects With Treatment Success, Assessed Per the Investigator's Static Global Assessment (ISGA) — 31; 8 particpants — p=0.058
Penile Cancer
Primary: Number of Participants With Pathologic Complete Remission (pCR) — 3 participants
Acne
Primary: Local Tolerability Was Analyzed in Terms of Worst Score Post-Baseline. — 4.23; 3.06; 3.25; 4.13 Scores on a scale
Rheumatoid Arthritis
Primary: Total Exposure to Etanercept With Gaps — 2882.50 Participant-years
Alcohol Dependence
Primary: Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While in Study — 143; 130 Participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) — -4.450; -4.148 percentage (%) of total haemoglobin
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of…
Sun Protection
Primary: Determination of Sunscreen Protection Factor (SPF) — 14.72; 15.00 Score on a scale
Neuroendocrine Carcinoma · Islet Cell Carcinoma
Primary: Progression Free Survival (PFS) — 60 Weeks
Primary Peritoneal Carcinoma · Tumor · Epithelial Ovarian Cancer
Primary: Number of Participants Experiencing Serious Adverse Events and Non-serious Adverse Events